This page describes activities of Euro-CNS that are not covered in a specific program elsewhere on this website.
Associate Society of the European Society of Pathology
In 2016, Euro-CNS joined the European Society of Pathology (ESP) as an Associate Society. The purpose of the partnership is to guarantee the continuity, stability, and visibility of neuropathology. A major task for Euro-CNS is to contribute for the ESP Congresses scientific and instructive program proposals focusing on neuropathology issues relevant for general pathology. The Euro-CNS proposals for scientific neuropathology sessions and workshops for the ESP2017 were accepted by the Scientific Program Committee of the ESP. Euro-CNS is now very pleased to announce the following sessions at the ESP Congress in Amsterdam in September 2017 as being coordinated by Euro-CNS:
5 September 2017
Long Course: How to handle neuropathological issues at autopsy?
Symposium: The pathological diagnosis of inflammatory myopathies
Short Course: The pathological diagnosis of CNS Tumours: tips and tricks for a down to earth approach
6 September 2017
Videomicroscopy: CNS Tumours
For the detailed program please visit the ESP congress webpage:
Assessment of the translational status of diagnostic molecular marker testing in adult diffuse glioma
Euro-CNS also engages in Patterns of diagnostic marker assessment in adult diffuse glioma: “Adelheid Wöhrer et al. present the results of a Euro-CNS survey on patterns of diagnostic marker assessment in diffuse glioma. This Euro-CNS survey is the first of its kind and shall set a baseline for future follow-up surveys. A total of 130 colleagues engaged in brain tumor diagnostics from 40 nations participated, including also representatives from a number of countries outside of Europe. The main aim of the survey was to assess the translational status of diagnostic molecular marker testing in diffuse gliomas after the release of the WHO 2016 brain tumor classification. The WHO 2016 classification has introduced for the first time an integrated diagnostic approach incorporating both tumor morphology and molecular information. The responses show that molecular marker testing is uniformly considered as highly relevant, and in most centers, molecular information is incorporated already in diagnostic assessments. However, there are substantial differences in access to molecular markers and techniques, and there is also a high level of heterogeneity of methods and platforms used for testing, even within the same countries. Further, the respondents express a high level of concern with regard to the validity of test assays and advocate the need for international harmonization of standards and consensus guidelines. The majority expressed willingness to actively engage in interlaboratory trials aiming at quality control. Euro-CNS could serve in future as a platform for the development of such international trials within Europe and beyond.” Quoted from the Editorial by Johannes Hainfellner in Clinical Neuropathology 2017-1. For the published results of the survey click here.